Biolife solutions stock.

BioLife Solutions is a class-defining cell and gene therapy bioproduction tools and services company. Our solutions give life science companies and clinical researchers significant improvement in shelf life and post-preservation viability and function of biological materials. BioLife Solutions is one of Washington’s best places to work ...BioLife Solutions Reports First Quarter 2023 Financial Results. Revenue of $37.7 million increased 4% over Q1 2022, ex-COVID growth of 16% and biopreservation media revenue growth of 28%. Q1 2023 ...Stock Information. The interactive chart below shows a historical timeline of our stock price and trading volume. Click on the tabs below to view the different timeframes. You may also view data on Dividend, Split, and Earning History by using the Events tab. NASDAQBLFS. 5d. 1m. 3m. 6m.BioLife recently disclosed its financial results for the fourth quarter of 2022, showcasing solid revenue growth and a better gross margin. In Q4 2022, the company brought in $44.3 million in ...Mar 22, 2021 · With Stirling, BioLife believes that total GAAP revenue in 2021 will exceed $100 million and the transaction is expected to be accretive on an adjusted Net Income per share basis (Non-GAAP) in ...

BOTHELL, Wash., Jan. 10, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapy (CGT) and broader biopharma markets, today announced preliminary revenue for the fourth quarter and full year 2021.Description. BioLife Solutions Inc is active in the healthcare segment. The company is engaged in developing, manufacturing and marketing a portfolio of biopreservation tools and services for cells, tissues and organs, including clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud, hosted ...

BioLife Solutions Stock Prediction 2030. In 2030, the BioLife Solutions stock will reach $ 450.79 if it maintains its current 10-year average growth rate. If this BioLife Solutions stock prediction for 2030 materializes, BLFS stock willgrow 3,789.49% from its current price.

BioLife Solutions, Inc. : News, information and stories for BioLife Solutions, Inc. | Other OTC: | Other OTCMay 19, 2023 · Shareholder Director Nominations. The Board of Directors of BioLife Solutions, Inc., a Delaware corporation, (the " Company ") determined that the Company's 2023 Annual Meeting of Stockholders (the " Annual Meeting ") will be held on July 21, 2023. It is expected that the Annual Meeting will be held virtually on the internet, but the time and ... Track Biolife Solutions Inc (BLFS) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsBOTHELL, Wash., July 7, 2020 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction tools for cell and gene therapies, today announced the closing of its public offering of 5,951,250 shares of common stock at the public offering price of $14.50 …

BOTHELL, Wash., Oct. 4, 2021 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) a leading developer and supplier of class-defining bioproduction products and services for cell and gene therapies and the broader biopharma market, today announced a broad engagement with a leading cell therapy developer, wherein BioLife's CryoStor freeze …

BioLife Solutions is reaffirming 2023 revenue guidance, which is based on expectations for its existing business. Total revenue for 2023 is expected to range from $188 million to $202 million ...

First, BioLife Solutions, Inc. stock is trading at 1.95x book value of equity, which may or may not represent a value proposition. However, it should also be noted the breakdown of its book value ...Aug 9, 2022 · BOTHELL, Wash., Aug. 9, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapies ("CGT") and the broader biopharma markets, today announced financial results for the three and six months ended ... Total revenue for the third quarter of 2023 was $33.3 million, a decrease of $7.4 million, or 18%, from $40.7 million for the third quarter of 2022. There was no COVID related revenue in the third ...Discover historical prices for BLFS stock on Yahoo Finance. View daily, weekly or monthly format back to when BioLife Solutions, Inc. stock was issued.BOTHELL, Wash., Aug. 9, 2021 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for cell and gene therapies and the broader biopharma market, today announced that it has entered into a definitive agreement to acquire all remaining outstanding shares of privately held Sexton ...CryoStor®CS10 effectively mitigates temperature-induced molecular cell stress responses to maximize post-thaw viability and recovery for a variety of immune cell types, including T cells (data not shown) and B cells. Here, human B cells from 6 different donors cryopreserved in CryoStor®CS10 show reproducibly high viability after thawing, as ...BioLife Solutions Inc. Watch NEW Set a price target alert After Hours Last Updated: Nov 24, 2023 4:04 p.m. EST Delayed quote $ 14.00 -0.08 -0.57% After Hours Volume: 1.96K …

On average, Wall Street analysts predict. that Biolife Solutions's share price could reach $25.50 by Aug 10, 2024. The average Biolife Solutions stock price prediction forecasts a potential upside of 103.84% from the current BLFS share price of $12.51. The estimated net worth of Roderick de Greef is at least $463,582.14 as of November 30th, 2022. Mr. de Greef owns 34,314 shares of BioLife Solutions stock worth more than $463,582 as of November 20th. This net worth estimate does not reflect any other investments that Mr. de Greef may own.BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.BioLife Solutions GAAP EPS of -$0.17 beats by $0.09, revenue of $36.22M misses by $1.98M SA News Mon, May 09, 2022 BioLife Solutions gains as Oppenheimer upgrades on valuationBioLife issued 6,646,870 shares of common stock in exchange for 100% of the outstanding shares of Stirling. BioLife management has provided guidance for Stirling's 2021 post-closing revenue contribution to be $35 million to $37 million , with total 2021 revenue of $101 million to $110 million .$26.0 ( 109.85% upside) Analyst Consensus: Strong Buy Stock ForecastsBOTHELL, Wash., Sept. 1, 2021 / PRNewswire / -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for cell and gene therapies and the broader biopharma market, today announced that it has closed its acquisition of Sexton Biotechnologies ...

CryoStor®CS10 effectively mitigates temperature-induced molecular cell stress responses to maximize post-thaw viability and recovery for a variety of immune cell types, including T cells (data not shown) and B cells. Here, human B cells from 6 different donors cryopreserved in CryoStor®CS10 show reproducibly high viability after thawing, as ...

Aug 8, 2023 · BioLife Solutions is updating 2023 revenue guidance, which is based on expectations for its existing business. Total revenue for 2023 is expected to range from $144 million to $158 million ... The estimated net worth of Marcus Schulz is at least $465,171.85 as of August 25th, 2023. Mr. Schulz owns 42,097 shares of BioLife Solutions stock worth more than $465,172 as of November 2nd. This net worth approximation does not reflect any other investments that Mr. Schulz may own. Learn More about Marcus Schulz's net worth.BOTHELL, Wash., July 7, 2020 / PRNewswire / -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction tools for cell and gene therapies, today announced the closing of its public offering of 5,951,250 shares of common stock at the public offering price ...Dec 1, 2023 · BioLife Solutions (NASDAQ:BLFS) and Zynex (NASDAQ:ZYXI) are both small-cap medical companies, but which is the superior stock?We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations, institutional ownership, media sentiment and community ranking. Penny stocks may sound like an interesting investment option, but there are some things that you should consider before deciding whether this is the right investment choice for you.Aug 9, 2023 · What happened. Shares of BioLife Solutions ( BLFS 3.76%) were down by more than 27% as of 1:15 p.m. on Wednesday after the healthcare company posted its second-quarter earnings report. The stock ... /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), ... for $24.0 million, in consideration for 506,382 newly issued shares of BioLife common stock. Taking into ...Aug 11, 2023 · Shares of BioLife Solutions (BLFS 7.11%) were down more than 37% for the week, as of 3:15 p.m. ET on Friday, ... The healthcare company's stock closed last week at $19.22, then dropped to a 52 ... Get the latest BioLife Solutions Inc (BLFS) stock quote, charts, news, and other financial information to help you make more informed trading and investment decisions. See the company's financial performance, balance sheet, cash flow, and earnings per share for the fiscal Q2 2023 ended 6/30/23. The entity was merged with our wholly-owned subsidiary, BioLife Solutions, Inc., which was engaged as a developer and marketer of biopreservation media products for cells and tissues. Following the merger, we changed our name to BioLife Solutions, Inc. Principal Offices; Available Information

BioLife Solutions, Inc. announced that it has received $10.374976 million in funding from Casdin Capital, LLC. Oct. 18. CI. Lake Street Adjusts Price Target on BioLife Solutions to $25 From $34, Maintains Buy Rating. Aug. 09. MT. Transcript : BioLife Solutions, Inc., Q2 2023 Earnings Call, Aug 08, 2023. Aug. 08.

Shares of BioLife Solutions ( BLFS 7.11%) were down more than 37% for the week, as of 3:15 p.m. ET on Friday, according to data provided by S&P Global Market Intelligence. The healthcare company's ...

Four times named as one of the top 100 Companies to work for in Washington state (2022, 2020, 2015, and 2013), BioLife Solutions Inc. is a multi-platform provider of bioproduction tools and services to the cell and gene therapy and broader biopharma markets. Learn more. What's going on at BioLife Solutions (NASDAQ:BLFS)? Read today's BLFS news from trusted media outlets at MarketBeat.Track Biolife Solutions Inc (BLFS) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors Biolife Solutions releases figures for Q3 on November 9. Wall Street analysts predict losses per share of $0.364. Go here to track Biolife Solutions stock price in real-time ahead of earnings.Discover historical prices for BLFS stock on Yahoo Finance. View daily, weekly or monthly format back to when BioLife Solutions, Inc. stock was issued. Shares of BioLife Solutions, Inc. (NASDAQ:BLFS) have received a favorable rating from five investment analysts, according to Bloomberg. These analysts Favorable Analyst Ratings and Growth Potential in BioLife Solutions, Inc. - Best StocksThe estimated net worth of Sarah Aebersold is at least $571,339.17 as of July 24th, 2023. Ms. Aebersold owns 43,983 shares of BioLife Solutions stock worth more than $571,339 as of October 12th. This net worth evaluation does not reflect any other assets that Ms. Aebersold may own. Learn More about Sarah Aebersold's net worth.Wall Street Stock Market & Finance report, prediction for the future: You'll find the Biolife Solutions share forecasts, stock quote and buy / sell signals below. According to present data Biolife Solutions's BLFS shares and potentially its market environment have been in bearish cycle last 12 months (if exists). Jan 5, 2023 · First, BioLife Solutions, Inc. stock is trading at 1.95x book value of equity, which may or may not represent a value proposition. However, it should also be noted the breakdown of its book value ... May 3, 2021 · BioLife issued 6,646,870 shares of common stock in exchange for 100% of the outstanding shares of Stirling. BioLife management has provided guidance for Stirling's 2021 post-closing revenue contribution to be $35 million to $37 million , with total 2021 revenue of $101 million to $110 million . This report will help you with various insights regarding the recent year performance of BioLife Solutions Inc (BLFS) stock.Open 18.44. Day High 18.95. Day Low 18.17. Prev Close 18.25. 52 Week High 26.96. 52 Week High Date 09/08/22. 52 Week Low 10.40. 52 Week Low Date 05/12/22. Market Cap 812.385M.

BioLife Solutions is a leading supplier of class-defining cell and gene therapy bioproduction tools and services. Our tools portfolio includes our proprietary CryoStor® freeze media and ...Dec 1, 2023 · BioLife Solutions (NASDAQ:BLFS) and Zynex (NASDAQ:ZYXI) are both small-cap medical companies, but which is the superior stock?We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations, institutional ownership, media sentiment and community ranking. BioLife Solutions Stock Prediction 2030. In 2030, the BioLife Solutions stock will reach $ 450.79 if it maintains its current 10-year average growth rate. If this BioLife Solutions stock prediction for 2030 materializes, BLFS stock willgrow 3,789.49% from its current price.BioLife Solutions announces intent to purchase SAVSU Technologies shares outstanding. On July 8, 2019, BioLife issued a press release announcing that the company will purchase the remaining 56% of shares of SAVSU that BioLife does not presently own. The acquisition is expected to close within 45 days. BioLife’s relationship with SAVSU …Instagram:https://instagram. vanguard ftse social index fundwebsites like robinhoodmo stock dividendswhere to sale xbox 360 ... Stock, $0.001 par value of BioLife Solutions, Inc. shall be filed on behalf of the undersigned. November 27, 2020. (Date). Casdin Capital, LLC. By: /s/ Eli ... uphold reviewsproperty investment groups BioLife Solutions, Inc. (BLFS) delivered earnings and revenue surprises of -27.78% and 10.07%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the ... amc buy See BioLife Solutions, Inc. (BLFS) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades.Dec 4, 2023 · Rhumbline Advisers decreased its holdings in BioLife Solutions, Inc. (NASDAQ:BLFS – Free Report) by 8.1% in the second quarter, Holdings Channel.com reports. The institutional investor owned 80,251 shares of the medical equipment provider’s stock after selling 7,097 shares during the period. Rhumbline Advisers’ holdings in BioLife Solutions were worth $1,774,000 as of its most recent […]